Risk of non-Hodgkin lymphoma and use of non-steroidal anti-inflammatory drugs

被引:10
|
作者
Zhang, YQ [1 ]
Coogan, PF
Palmer, JR
Strom, BL
Rosenberg, L
机构
[1] Boston Univ, Sch Med, Clin Epidemiol Res & Training Unit, Boston, MA 02118 USA
[2] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA
[3] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Div Gen Internal Med, Dept Med, Philadelphia, PA 19104 USA
来源
CANCER DETECTION AND PREVENTION | 2006年 / 30卷 / 01期
关键词
non-Hodgkin lymphoma; non-steroidal anti-inflammatory drug; case-control studies; risk factors;
D O I
10.1016/j.cdp.2005.12.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Risk factors for non-Hodgkin lymphoma (NHL) are largely unknown. Several studies have examined the relation of nonsteroidal anti-inflammatory drug (NSAID) use to the risk of NHL, with inconsistent results. Methods: We examined NSAID use among 529 newly diagnosed NHL cases and 2013 controls interviewed from 1977 to 2002 in our Case-Control Surveillance Study. Results: The odds ratio for NHL among subjects whose regular NSAID use began at least one year prior to hospital admission compared to never users was 0.9 (95% confidence interval (CI): 0.6-1.3). Odds ratios for less than five years, five to less than 10 years, and 10 or more years of regular use were 1.2 (95% CI: 0.8-1.9), 1.0 (95% CI: 0.5-2.1), and 0.4 (95% CI: 0.1-1.0), respectively. The results were similar for regular aspirin use. Conclusion: Our results add to the body of data suggesting that NSAIDs do not increase the risk of NHL and even suggest the possibility of protection by long-term use. (c) 2006 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:99 / 101
页数:3
相关论文
共 50 条